<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/PURPOSE: Behavioral and psychologic symptoms of <z:hpo ids='HP_0000726'>dementia</z:hpo> (BPSD) are major sources of a caregiver's burden and also the most important factor when considering the need for institutionalization of <z:hpo ids='HP_0000726'>dementia</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>BPSD occur in about 90% of patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Studies comparing the BPSD in the major types of <z:hpo ids='HP_0000726'>dementia</z:hpo> using unitary behavioral rating scales are limited </plain></SENT>
<SENT sid="3" pm="."><plain>We studied BPSD in patients with four major types of <z:hpo ids='HP_0000726'>dementias</z:hpo> from a memory clinic </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We recruited patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> from our memory clinic from January 2003 to February 2004 </plain></SENT>
<SENT sid="5" pm="."><plain>The Behavioral Pathology in <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> Rating Scale (BEHAVE-AD) was used to measure BPSD severity </plain></SENT>
<SENT sid="6" pm="."><plain>Clinical <z:hpo ids='HP_0000726'>Dementia</z:hpo> Rating and Mini Mental State Examination were used to determine <z:hpo ids='HP_0000726'>dementia</z:hpo> severity </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: A total of 137 patients with four major types of <z:hpo ids='HP_0000726'>dementia</z:hpo> were recruited from 155 patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> who attended the clinic during the study period </plain></SENT>
<SENT sid="8" pm="."><plain>The main <z:hpo ids='HP_0000726'>dementia</z:hpo> types identified were Alzheimer's <z:hpo ids='HP_0000726'>dementia</z:hpo> (AD) in 54.8%, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) in 20.6%, <z:hpo ids='HP_0002145'>frontotemporal dementia</z:hpo> (FTD) in 8.4%, <z:hpo ids='HP_0000726'>dementia</z:hpo> with <z:hpo ids='HP_0100315'>Lewy bodies</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>) in 4.5%, and other <z:hpo ids='HP_0000726'>dementias</z:hpo> in 11.6% </plain></SENT>
<SENT sid="9" pm="."><plain>BPSD were found in 92.0% of the patients but only 43.1% received psychotropic treatment </plain></SENT>
<SENT sid="10" pm="."><plain>The relative risk of receiving psychotropic treatment for BPSD subscales paralleled the extent of caregivers' burden as assessed by the BEHAVE-AD global rating </plain></SENT>
<SENT sid="11" pm="."><plain>Type-specific BPSD, e.g. <z:hpo ids='HP_0000738'>hallucination</z:hpo> was identified for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e>, activity disturbances for FTD, <z:hpo ids='HP_0000739'>anxiety</z:hpo> and <z:e sem="disease" ids="C0349231" disease_type="Mental or Behavioral Dysfunction" abbrv="">phobias</z:e> for AD and affective disturbance for VaD </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: A strategy of targeting type-specific BPSD may be beneficial, such as environmental stimulus control for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLB</z:e> patients who are prone to have <z:hpo ids='HP_0000738'>hallucinations</z:hpo>, design of a pacing path for patients with FTD who need support for symptoms of wandering and emotional support for patients with VaD who are susceptible to <z:hpo ids='HP_0000716'>depression</z:hpo> </plain></SENT>
</text></document>